NexGen LPS-Flex/LPS Mobile Bearing Knee System
Zimmer, Inc. · Decision date Oct 16, 2026
What did the FDA decide?
The FDA record for P060037/S100 lists Zimmer, Inc. as applicant for the NexGen LPS-Flex/LPS Mobile Bearing Knee System and carries the decision code OK30 dated 2026-10-16. The filing is a 30-Day Notice for a process change under the manufacturer/sterilizer/packager/supplier category. The stated change is expansion of ISO Class 7 packaging cleanroom space and corridor at the Zimmer Inc Warsaw West facility. The notice concerns packaging environment space, not a device design or labeling change.
The identifier places this as supplement S100 to PMA P060037, which the record ties to the knee prosthesis category, product code NJL. It is not an approval of the whole knee system, and a manufacturing notice is not an original PMA. The source statement gives no room dimensions, no validation data, no packaging-material change, and no evidence of safety or clinical effectiveness; whether the expansion affects sterility assurance or product performance is not stated in the supplied fields.
FDA approval order statement
expansion of ISO Class 7 packaging cleanroom space and corridor at the Zimmer Inc Warsaw West facility
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Oct 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P060037/S100
- Regulatory pathway
- PMA supplement
- Applicant
- Zimmer, Inc.
- Product code
- NJL
- Decision code
- OK30
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, knee, patellofemorotibial, semi-constrained, metal/polymer, mobile bearing.
- Applicant
- Zimmer, Inc.
- Product code
- NJL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P060037. Subsequent supplements may change the device or its indications.
FDA decision timeline
P060037 · Original PMA
NEXGEN LPS-FLEX MOBILE AND LPS-MOBILE BEARING KNEE SYSTEM
P060037/S099 · Related supplement
NexGen LPS-Flex Mobile and LPS-Mobile Bearing Knee System
P060037/S100 received
Application receipt date recorded by FDA.
P060037/S100 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P060037. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P060037
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Zimmer, Inc. | PMA approval | Dec 10, 2007 | FDA | |
| Zimmer, Inc. | PMA supplement | Sep 24, 2026 | FDA |
Explore the linked device profile
Other records with product code NJL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LCS Knee SystemP830055/S378 | Depuy, Inc. | PMA supplement | Oct 27, 2026 | FDA |
| Depuy, Inc. | PMA supplement | Oct 27, 2026 | FDA | |
ATTUNE Revision Knee SystemP830055/S379 | Depuy, Inc. | PMA supplement | Oct 9, 2026 | FDA |
| Depuy, Inc. | PMA supplement | Oct 8, 2026 | FDA | |
LCS Total Knee SystemP830055/S380 | Depuy, Inc. | PMA supplement | Oct 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Zimmer, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- P.O. Box 708, Warsaw, IN, 46581
Sources and methodology
- Original FDA record: P060037/S100
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


